NTUS Natus Medical Incorporated

DEADLINE ALERT: Brower Piven Reminds Investors of the March 31, 2017 Deadline in Class Action Lawsuit and Encourages Investors with Losses in Excess of $100,000 from Investment in Natus Medical Incorporated to Contact the Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Natus Medical Incorporated (Nasdaq: BABY) (“Natus” or the “Company”) common stock during the period between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 31, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Natus common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that: the government of Venezuela failed to make tens of millions of dollars in prepayments to Natus, which were required to be paid in October 2015; Natus could not effectively enforce its rights under its supply contract and its revenues related to the supply contract were dependent on the outcome of Venezuelan elections; and, Natus could not effectively achieve its guidance.

According to the complaint, following a January 11, 2016 announcement that Venezuela had not made expected payments due to a delay, a January 27, 2016 announcement reaffirming a revenue shortfall due to the delay, a February 29, 2016 filing disclosing that the prepayments were due in October 2015, and an April 4, 2016 announcement that the Company still had not received the prepayments and the Company missed its guidance, the value of Natus shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Natus common stock purchased on or after October 16, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
21/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Natus Medical Incorporated

 PRESS RELEASE

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 ...

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive ...

 PRESS RELEASE

Natus Medical Announces First Quarter 2022 Financial Results

Natus Medical Announces First Quarter 2022 Financial Results  Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22     MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022...

 PRESS RELEASE

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50...

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announce...

 PRESS RELEASE

Natus Medical to Hold 2022 First Quarter Financial Results Conference ...

Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern...

 PRESS RELEASE

Natus Medical Announces Fourth Quarter 2021 Financial Results

Natus Medical Announces Fourth Quarter 2021 Financial Results  Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47     PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch